Kwai Logo
Kwai User Avatar
1 de abr. 2022 Anvisa autoriza uso emergencial do Paxlovid para tratar covid-19 A Agência Nacional de Vigilância Sanitária autorizou o uso emergencial do medicamento Paxlovid para tratar a covid-19. A aprovação é de forma experimental e temporária. O remédio já é usado, também de forma emergencial, em países da União Europeia e nos Estados Unidos. Veja quando o antiviral deve ser usado e como ele atua no organismo, na reportagem da Rede Minas. Além disso, o Sistema Único de Saúde (SU
33
3
30 de mar. 2022 Anvisa decide hoje se autoriza uso emergencial do Paxlovid, medicamento contra covid-19 A diretoria da Agência Nacional de Vigilância Sanitária se reúne na tarde desta quarta-feira para avaliar o uso emergencial do Paxlovid, medicamento contra a covid-19. Segundo a fabricante, o antiviral, quando administrado no início da infecção, reduz os casos de hospitalização e mortes pela doença. A autorização, caso seja aprovada, é de uso emergencial, temporária e experime
11
1
16 de jun. 2022 Estudos clínicos com paxlovid são suspensos A Pfizer decidiu suspender o estudo clínico para testar a eficácia do medicamento paxlovid no tratamento de pacientes com baixo risco de evolução para covid-19 grave. A análise preliminar do estudo não mostrou diminuição significativa no tempo de sintomas e internação entre os pacientes de baixo risco que participavam da pesquisa.
24
Comment
Loading
kwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwaikwai kwaikwaikwaikwaikwaikwaikwaikwaikwaikwai